Dr. Temeles, intellectual property lawyer and Palo Santo Scientific Advisory Board member, discusses the application of intellectual property law to psychedelic biotech.
Dr. Kwan, Associate Professor of Biomedical Engineering at Cornell, discusses his laboratory’s discoveries of psychedelic-induced neural plasticity.
Dr. Becker, CSO of Bexson Biomedical, comes to discuss his company’s novel ketamine administration technology for chronic pain patients.
Dr. Cameron, postdoctoral scholar at Stanford, discusses her seminal work characterizing DMT and the non-hallucinogenic psychoplastogen tabernanthalog during her PhD in the David Olson Lab at UC Davis.
Welcome to PsychExchange with Co-hosts Adrienne Jo & Sophie Rogers.